Literature DB >> 25840601

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Christophe Desterke1, Christophe Martinaud2, Bernadette Guerton3, Lisa Pieri4, Costanza Bogani4, Denis Clay1, Frederic Torossian1, Jean-Jacques Lataillade5, Hans C Hasselbach6, Heinz Gisslinger7, Jean-Loup Demory8, Brigitte Dupriez9, Claude Boucheix10, Eric Rubinstein10, Sophie Amsellem11, Alessandro M Vannucchi4, Marie-Caroline Le Bousse-Kerdilès12.   

Abstract

Primary myelofibrosis is characterized by clonal myeloproliferation, dysmegakaryopoiesis, extramedullary hematopoiesis associated with myelofibrosis and altered stroma in the bone marrow and spleen. The expression of CD9, a tetraspanin known to participate in megakaryopoiesis, platelet formation, cell migration and interaction with stroma, is deregulated in patients with primary myelofibrosis and is correlated with stage of myelofibrosis. We investigated whether CD9 participates in the dysmegakaryopoiesis observed in patients and whether it is involved in the altered interplay between megakaryocytes and stromal cells. We found that CD9 expression was modulated during megakaryocyte differentiation in primary myelofibrosis and that cell surface CD9 engagement by antibody ligation improved the dysmegakaryopoiesis by restoring the balance of MAPK and PI3K signaling. When co-cultured on bone marrow mesenchymal stromal cells from patients, megakaryocytes from patients with primary myelofibrosis displayed modified behaviors in terms of adhesion, cell survival and proliferation as compared to megakaryocytes from healthy donors. These modifications were reversed after antibody ligation of cell surface CD9, suggesting the participation of CD9 in the abnormal interplay between primary myelofibrosis megakaryocytes and stroma. Furthermore, silencing of CD9 reduced CXCL12 and CXCR4 expression in primary myelofibrosis megakaryocytes as well as their CXCL12-dependent migration. Collectively, our results indicate that CD9 plays a role in the dysmegakaryopoiesis that occurs in primary myelofibrosis and affects interactions between megakaryocytes and bone marrow stromal cells. These results strengthen the "bad seed in bad soil" hypothesis that we have previously proposed, in which alterations of reciprocal interactions between hematopoietic and stromal cells participate in the pathogenesis of primary myelofibrosis. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25840601      PMCID: PMC4450621          DOI: 10.3324/haematol.2014.118497

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  45 in total

1.  SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients.

Authors:  T L Lasho; C M Finke; C A Hanson; T Jimma; R A Knudson; R P Ketterling; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

2.  Molecular cloning of the CD9 antigen. A new family of cell surface proteins.

Authors:  C Boucheix; P Benoit; P Frachet; M Billard; R E Worthington; J Gagnon; G Uzan
Journal:  J Biol Chem       Date:  1991-01-05       Impact factor: 5.157

3.  Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; A Grossi; B Comotti; P Musto; G Gamba; M Marchetti
Journal:  Br J Haematol       Date:  2001-07       Impact factor: 6.998

4.  GSK-3β negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro.

Authors:  Mayumi Ono; Yumiko Matsubara; Toshiro Shibano; Yasuo Ikeda; Mitsuru Murata
Journal:  Platelets       Date:  2011-01-13       Impact factor: 3.862

5.  CD9 and megakaryocyte differentiation.

Authors:  D Clay; E Rubinstein; Z Mishal; A Anjo; M Prenant; C Jasmin; C Boucheix; M C Le Bousse-Kerdilès
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

6.  Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.

Authors:  Alessandro M Vannucchi; Alessandro Pancrazzi; Paola Guglielmelli; Simonetta Di Lollo; Costanza Bogani; Gianna Baroni; Lucia Bianchi; Anna Rita Migliaccio; Alberto Bosi; Francesco Paoletti
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

7.  Upregulation of CD9 expression during TPA treatment of K562 cells.

Authors:  F Le Naour; C Francastel; M Prenant; O Lantz; C Boucheix; E Rubinstein
Journal:  Leukemia       Date:  1997-08       Impact factor: 11.528

8.  The Jun family members, c-Jun and JunD, transactivate the human c-myb promoter via an Ap1-like element.

Authors:  N C Nicolaides; I Correa; C Casadevall; S Travali; K J Soprano; B Calabretta
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

9.  A novel therapeutic strategy with anti-CD9 antibody in gastric cancers.

Authors:  Taisei Nakamoto; Yoko Murayama; Kenji Oritani; Claude Boucheix; Eric Rubinstein; Makoto Nishida; Fumie Katsube; Kenji Watabe; Shinichi Kiso; Shusaku Tsutsui; Shinji Tamura; Yasuhisa Shinomura; Norio Hayashi
Journal:  J Gastroenterol       Date:  2009-05-26       Impact factor: 7.527

10.  GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms.

Authors:  Kyoko Kitagawa; Yojiro Kotake; Yoshihiro Hiramatsu; Ning Liu; Sayuri Suzuki; Satoki Nakamura; Akira Kikuchi; Masatoshi Kitagawa
Journal:  Cell Div       Date:  2010-11-21       Impact factor: 5.130

View more
  4 in total

1.  Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity.

Authors:  Praveen K Suraneni; Seth J Corey; Michael J Hession; Rameez Ishaq; Arinola Awomolo; Shirin Hasan; Chirag Shah; Hui Liu; Amittha Wickrema; Najet Debili; John D Crispino; Elizabeth A Eklund; Yolande Chen
Journal:  Blood Adv       Date:  2018-12-11

Review 2.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

3.  Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Authors:  Christophe Martinaud; Christophe Desterke; Johanna Konopacki; Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli; Brigitte Dupriez; Jean-Christophe Ianotto; Laetitia Boutin; Jean-Jacques Lataillade; Marie-Caroline Le Bousse-Kerdilès
Journal:  Genom Data       Date:  2015-04-29

Review 4.  Role of the microenvironment in myeloid malignancies.

Authors:  Marie Goulard; Christine Dosquet; Dominique Bonnet
Journal:  Cell Mol Life Sci       Date:  2017-12-08       Impact factor: 9.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.